Pulmonary hypertension and right ventricular function in advanced heart failure

Congestive Heart Failure

Volumn 17, Issue 4, 2011, Pages 189-198

  Kalogeropoulos, Andreas P ^a,b   Vega, J David ^b   Smith, Andrew L ^a   Georgiopoulou, Vasiliki V ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BOSENTAN; DARUSENTAN; ENDOTHELIN 1; GUANOSINE PHOSPHATE; NITRIC OXIDE; PROSTACYCLIN; SILDENAFIL;

ABSENCE OF SIDE EFFECTS; ADVANCED HEART FAILURE; ARTERIAL STIFFNESS; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL DECISION MAKING; DIASTOLIC DYSFUNCTION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FOLLOW UP; GENETIC PREDISPOSITION; HEART AFTERLOAD; HEART CATHETERIZATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FILLING PRESSURE; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART SURGERY; HEART TRANSPLANTATION; HUMAN; HYPOKINESIA; LEFT VENTRICULAR ASSIST DEVICE; LOW DRUG DOSE; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MITRAL VALVE REGURGITATION; MONOTHERAPY; MORBIDITY; MORTALITY; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROGNOSIS; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; REVIEW; SURGICAL VENTRICULAR RECONSTRUCTION; SURVIVAL RATE; SURVIVAL TIME; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION; TISSUE DOPPLER IMAGING; UNSPECIFIED SIDE EFFECT;

COMORBIDITY; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE 5 INHIBITORS; PREVALENCE; PROGNOSIS; VASCULAR RESISTANCE; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR FUNCTION, RIGHT;

EID: 79960714036     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2011.00234.x     Document Type: Review

References (123)

1. Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation. 2000;102(14):1718-1723.
2. Khush KK, Tasissa G, Butler J, et al., ESCAPE Investigators. Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: analysis of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) database. Am Heart J. 2009;157(6):1026-1034.
3. Cappola TP, Felker GM, Kao WH, et al. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation. 2002;105(14):1663-1668.
4. Kjaergaard J, Akkan D, Iversen KK, et al. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol. 2007;99(8):1146-1150.
5. Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001;37(1):183-188.
6. Meyer P, Filippatos GS, Ahmed MI, et al. Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure. Circulation. 2010;121(2):252-258.
7. Damy T, Goode KM, Kallvikbacka-Bennett A, et al. Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure. Eur Heart J. 2010;31(18):2280-2290.
8. Guazzi M, Arena R. Pulmonary hypertension with left-sided heart disease. Nat Rev Cardiol. 2010;7(11):648-659.
9. Ooi H, Colucci WS, Givertz MM. Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan. Circulation. 2002;106(13):1618-1621.
10. Cooper CJ, Jevnikar FW, Walsh T, et al. The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure. Am J Cardiol. 1998;82(5):609-614.
11. Delgado JF, Conde E, Sánchez V, et al. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail. 2005;7(6):1011-1016.
12. Haddad F, Hunt SA, Rosenthal DN, Murphy DJ. Right ventricular function in cardiovascular disease, part I: anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation. 2008;117(11):1436-1448.
13. Hoeper MM. Definition, classification, and epidemiology of pulmonary arterial hypertension. Semin Respir Crit Care Med. 2009;30(4):369-375.
14. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30(20):2493-2537.
15. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S43-S54.
16. Goland S, Czer LS, Kass RM, et al. Pre-existing pulmonary hypertension in patients with end-stage heart failure: impact on clinical outcome and hemodynamic follow-up after orthotopic heart transplantation. J Heart Lung Transplant. 2007;26(4):312-318.
17. Mikus E, Stepanenko A, Krabatsch T, et al. Left ventricular assist device or heart transplantation: impact of transpulmonary gradient and pulmonary vascular resistance on decision making. Eur J Cardiothorac Surg. 2011;39(3):310-316.
18. Costard-Jäckle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol. 1992;19(1):48-54.
19. Costanzo MR, Augustine S, Bourge R, et al. Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation. 1995;92(12):3593-3612.
20. Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates - 2006. J Heart Lung Transplant. 2006;25(9):1024-1042.
21. Bacal F, de Freitas AF, Moreira LF, et al. Validation of a cutoff value on echo Doppler analysis to replace right heart catheterization during pulmonary hypertension evaluation in heart transplant candidates. Transplant Proc. 2010;42(2):535-538.
22. Kuppahally SS, Michaels AD, Tandar A, et al. Can echocardiographic evaluation of cardiopulmonary hemodynamics decrease right heart catheterizations in end-stage heart failure patients awaiting transplantation? Am J Cardiol. 2010;106(11):1657-1662.
23. McDonald MA, Ross HJ. Trying to succeed when the right ventricle fails. Curr Opin Cardiol. 2009;24(3):239-245.
24. Bhave NM, Ward RP. Echocardiographic assessment and clinical management of tricuspid regurgitation. Curr Cardiol Rep. 2011;13(3):258-264.
25. Givertz MM, Hare JM, Loh E, et al. Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension. J Am Coll Cardiol. 1996;28(7):1775-1780.
26. Schulze-Neick I, Luther YC, Ewert P, et al. End-stage heart failure with pulmonary hypertension: levosimendan to evaluate for heart transplantation alone versus combined heart-lung transplantation. Transplantation. 2004;78(8):1237-1238.
27. Semigran MJ, Cockrill BA, Kacmarek R, et al. Hemodynamic effects of inhaled nitric oxide in heart failure. J Am Coll Cardiol. 1994;24(4):982-988.
28. Haywood GA, Sneddon JF, Bashir Y, et al. Adenosine infusion for the reversal of pulmonary vasoconstriction in biventricular failure. A good test but a poor therapy. Circulation. 1992;86(3):896-902.
29. Murali S, Uretsky BF, Reddy PS, et al. Reversibility of pulmonary hypertension in congestive heart failure patients evaluated for cardiac transplantation: comparative effects of various pharmacologic agents. Am Heart J. 1991;122(5):1375-1381.
30. Montalescot G, Drobinski G, Meurin P, et al. Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure. Am J Cardiol. 1998;82(6):749-755.
31. Klotz S, Deng MC, Hanafy D, et al. Reversible pulmonary hypertension in heart transplant candidates - pretransplant evaluation and outcome after orthotopic heart transplantation. Eur J Heart Fail. 2003;5(5):645-653.
32. Braun S, Schrötter H, Schmeisser A, Strasser RH. Evaluation of pulmonary vascular response to inhaled iloprost in heart transplant candidates with pulmonary venous hypertension. Int J Cardiol. 2007;115(1):67-72.
33. Botha P, Parry G, Dark JH, Macgowan GA. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. J Heart Lung Transplant. 2009;28(7):676-682.
34. Torres Macho J, Delgado Jimenez JF, Sanz Salvo J, et al. Effect of different pharmacologic agents to reverse severe pulmonary hypertension among end-stage heart failure patients. Transplant Proc. 2009;41(6):2477-2479.
35. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440-1463.
36. Matthews JC, Dardas TF, Dorsch MP, Aaronson KD. Right-sided heart failure: diagnosis and treatment strategies. Curr Treat Options Cardiovasc Med. 2008;10(4):329-341.
37. Meluzín J, Spinarová L, Bakala J, et al. Pulsed Doppler tissue imaging of the velocity of tricuspid annular systolic motion; a new, rapid, and non-invasive method of evaluating right ventricular systolic function. Eur Heart J. 2001;22(4):340-348.
38. Zornoff LA, Skali H, Pfeffer MA, et al. Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. J Am Coll Cardiol. 2002;39(9):1450-1455.
39. Spinarová L, Meluzín J, Toman J, et al. Right ventricular dysfunction in chronic heart failure patients. Eur J Heart Fail. 2005;7(4):485-489.
40. Meluzin J, Spinarová L, Hude P, et al. Prognostic importance of various echocardiographic right ventricular functional parameters in patients with symptomatic heart failure. J Am Soc Echocardiogr. 2005;18(5):435-444.
41. Dokainish H, Sengupta R, Patel R, Lakkis N. Usefulness of right ventricular tissue Doppler imaging to predict outcome in left ventricular heart failure independent of left ventricular diastolic function. Am J Cardiol. 2007;99(7):961-965.
42. Anavekar NS, Skali H, Bourgoun M, et al. Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study). Am J Cardiol. 2008;101(5):607-612.
43. Damy T, Viallet C, Lairez O, et al. Comparison of four right ventricular systolic echocardiographic parameters to predict adverse outcomes in chronic heart failure. Eur J Heart Fail. 2009;11(9):818-824.
44. Bistola V, Parissis JT, Paraskevaidis I, et al. Prognostic value of tissue Doppler right ventricular systolic and diastolic function indexes combined with plasma B-type natriuretic Peptide in patients with advanced heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2010;105(2):249-254.
45. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23(7):685-713. quiz 786-8.
46. Lam CS, Roger VL, Rodeheffer RJ, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53(13):1119-1126.
47. Leung CC, Moondra V, Catherwood E, Andrus BW. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol. 2010;106(2):284-286.
48. Tumminello G, Lancellotti P, Lempereur M, et al. Determinants of pulmonary artery hypertension at rest and during exercise in patients with heart failure. Eur Heart J. 2007;28(5):569-574.
49. Patel JB, Borgeson DD, Barnes ME, et al. Mitral regurgitation in patients with advanced systolic heart failure. J Card Fail. 2004;10(4):285-291.
50. Olson TP, Snyder EM, Frantz RP, et al. Repeat length polymorphism of the serotonin transporter gene influences pulmonary artery pressure in heart failure. Am Heart J. 2007;153(3):426-432.
51. Gavazzi A, Ghio S, Scelsi L, et al. Response of the right ventricle to acute pulmonary vasodilation predicts the outcome in patients with advanced heart failure and pulmonary hypertension. Am Heart J. 2003;145(2):310-316.
52. Desai RV, Meyer P, Ahmed MI, et al. Relationship between left and right ventricular ejection fractions in chronic advanced systolic heart failure: insights from the BEST trial. Eur J Heart Fail. 2011;13(4):392-397.
53. Berkowitz R, Alhaj E, Manchikalapudi RB, et al. Determinants of right ventricular failure in patients admitted with acute left heart failure. Congest Heart Fail. 2010;16(6):243-248.
54. La Vecchia L, Zanolla L, Varotto L, et al. Reduced right ventricular ejection fraction as a marker for idiopathic dilated cardiomyopathy compared with ischemic left ventricular dysfunction. Am Heart J. 2001;142(1):181-189.
55. Butler J, Chomsky DB, Wilson JR. Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol. 1999;34(6):1802-1806.
56. Chang PP, Longenecker JC, Wang NY, et al. Mild vs severe pulmonary hypertension before heart transplantation: different effects on posttransplantation pulmonary hypertension and mortality. J Heart Lung Transplant. 2005;24(8):998-1007.
57. Puwanant S, Priester TC, Mookadam F, et al. Right ventricular function in patients with preserved and reduced ejection fraction heart failure. Eur J Echocardiogr. 2009;10(6):733-737.
58. Abramson SV, Burke JF, Kelly JJ, et al. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med. 1992;116(11):888-895.
59. Grigioni F, Potena L, Galiè N, et al. Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. J Heart Lung Transplant. 2006;25(10):1241-1246.
60. Reindl I, Wernecke KD, Opitz C, et al. Impaired ventilatory efficiency in chronic heart failure: possible role of pulmonary vasoconstriction. Am Heart J. 1998;136(5):778-785.
61. Filusch A, Ewert R, Altesellmeier M, et al. Respiratory muscle dysfunction in congestive heart failure-The role of pulmonary hypertension. Int J Cardiol. 2010; May 3; [Epub ahead of print].
62. Shalaby A, Voigt A, El-Saed A, Saba S. Usefulness of pulmonary artery pressure by echocardiography to predict outcome in patients receiving cardiac resynchronization therapy heart failure. Am J Cardiol. 2008;101(2):238-241.
63. Kainuma S, Taniguchi K, Toda K, et al. Pulmonary hypertension predicts adverse cardiac events after restrictive mitral annuloplasty for severe functional mitral regurgitation. J Thorac Cardiovasc Surg. 2011;March 11; [E-pub ahead of print].
64. Moreira LF, Benício A, Bacal F, et al. Determinants of long-term mortality of current palliative surgical treatment for dilated cardiomyopathy. Eur J Cardiothorac Surg. 2003;23(5):756-763. discussion 763-4.
65. Levine TB, Levine AB, Goldberg D, et al. Impact of medical therapy on pulmonary hypertension in patients with congestive heart failure awaiting cardiac transplantation. Am J Cardiol. 1996;78(4):440-443.
66. Ghio S. Pulmonary hypertension in advanced heart failure. Herz. 2005;30(4):311-317.
67. Kittleson MM, Kobashigawa JA. Management of advanced heart failure: the role of heart transplantation. Circulation. 2011;123(14):1569-1574.
68. Drakos SG, Kfoury AG, Gilbert EM, et al. Effect of reversible pulmonary hypertension on outcomes after heart transplantation. J Heart Lung Transplant. 2007;26(4):319-323.
69. Klotz S, Wenzelburger F, Stypmann J, et al. Reversible pulmonary hypertension in heart transplant candidates: to transplant or not to transplant. Ann Thorac Surg. 2006;82(5):1770-1773.
70. Di Salvo TG, Mathier M, Semigran MJ, Dec GW. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol. 1995;25(5):1143-1153.
71. Gavazzi A, Berzuini C, Campana C, et al. Value of right ventricular ejection fraction in predicting short-term prognosis of patients with severe chronic heart failure. J Heart Lung Transplant. 1997;16(7):774-785.
72. Karatasakis GT, Karagounis LA, Kalyvas PA, et al. Prognostic significance of echocardiographically estimated right ventricular shortening in advanced heart failure. Am J Cardiol. 1998;82(3):329-334.
73. Field ME, Solomon SD, Lewis EF, et al. Right ventricular dysfunction and adverse outcome in patients with advanced heart failure. J Card Fail. 2006;12(8):616-620.
74. Lewis GD, Shah RV, Pappagianopolas PP, et al. Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone. Circ Heart Fail. 2008;1(4):227-233.
75. D'Andrea A, Gravino R, Riegler L, et al. Right ventricular ejection fraction and left ventricular dyssynchrony by 3D echo correlate with functional impairment in patients with dilated cardiomyopathy. J Card Fail. 2011;17(4):309-317.
76. Verhaert D, Mullens W, Borowski A, et al. Right ventricular response to intensive medical therapy in advanced decompensated heart failure. Circ Heart Fail. 2010;3(3):340-346.
77. Cody RJ, Haas GJ, Binkley PF, et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85(2):504-509.
78. Pacher R, Stanek B, Hülsmann M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol. 1996;27(3):633-641.
79. Sütsch G, Kiowski W, Yan XW, et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation. 1998;98(21):2262-2268.
80. Spieker LE, Mitrovic V, Noll G, et al. Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators. J Am Coll Cardiol. 2000;35(7):1745-1752.
81. Givertz MM, Colucci WS, LeJemtel TH, et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation. 2000;101(25):2922-2927.
82. Lüscher TF, Enseleit F, Pacher R, et al. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation. 2002;106(21):2666-2672.
83. Mylona P, Cleland JG. Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. Eur J Heart Fail. 1999;1(2):197-200.
84. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol. 2002;85(2-3):195-197.
85. Anand IS, Wu T. Syndromes of subacute mountain sickness. High Alt Med Biol. 2004;5(2):156-170.
86. Packer M, McMurray J, Massie BM, et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail. 2005;11(1):12-20.
87. Kaluski E, Cotter G, Leitman M, et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension - a multi-center randomized study. Cardiology. 2008;109(4):273-280.
88. Hefke T, Zittermann A, Fuchs U, et al. Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation*. Thorac Cardiovasc Surg. 2011; March 22. [E-pub ahead of print].
89. Pacher R, Stanek B, Hülsmann M, Sinzinger H. Effect of prostaglandin E1 infusion in severe chronic heart failure. Prostaglandins. 1997;53(4):221-235.
90. Murali S, Uretsky BF, Armitage JM, et al. Utility of prostaglandin E1 in the pretransplantation evaluation of heart failure patients with significant pulmonary hypertension. J Heart Lung Transplant. 1992;11(4 Pt 1):716-723.
91. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134(1):44-54.
92. Serra W, Musiari L, Ardissino D, et al. Benefit of prostaglandin infusion in severe heart failure: preliminary clinical experience of repetitive administration. Int J Cardiol. 2011;146(1):e10-e15.
93. Melenovsky V, Al-Hiti H, Kazdova L, et al. Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil. J Am Coll Cardiol. 2009;54(7):595-600.
94. Kass DA, Champion HC, Beavo JA. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res. 2007;101(11):1084-1095.
95. Lepore JJ, Maroo A, Bigatello LM, et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest. 2005;127(5):1647-1653.
96. Lewis GD, Lachmann J, Camuso J, et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation. 2007;115(1):59-66.
97. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007;116(14):1555-1562.
98. Guazzi M, Samaja M. The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development. Curr Med Chem. 2007;14(20):2181-2191.
99. Behling A, Rohde LE, Colombo FC, et al. Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail. 2008;14(3):189-197.
100. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011;4(1):8-17.
101. Stehlik J, Movsesian MA. Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure. J Card Fail. 2009;15(1):31-34.
102. Klodell CT, Morey TE, Lobato EB, et al. Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices. Ann Thorac Surg. 2007;83(1):68-71. discussion 71.
103. Tedford RJ, Hemnes AR, Russell SD, et al. PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail. 2008;1(4):213-219.
104. Jabbour A, Keogh A, Hayward C, Macdonald P. Chronic sildenafil lowers transpulmonary gradient and improves cardiac output allowing successful heart transplantation. Eur J Heart Fail. 2007;9(6-7):674-677.
105. Zakliczynski M, Maruszewski M, Pyka L, et al. Effectiveness and safety of treatment with sildenafil for secondary pulmonary hypertension in heart transplant candidates. Transplant Proc. 2007;39(9):2856-2858.
106. Boffini M, Sansone F, Ceresa F, et al. Role of oral sildenafil in the treatment of right ventricular dysfunction after heart transplantation. Transplant Proc. 2009;41(4):1353-1356.
107. De Santo LS, Mastroianni C, Romano G, et al. Role of sildenafil in acute posttransplant right ventricular dysfunction: successful experience in 13 consecutive patients. Transplant Proc. 2008;40(6):2015-2018.
108. Haddad H, Elabbassi W, Moustafa S, et al. Left ventricular assist devices as bridge to heart transplantation in congestive heart failure with pulmonary hypertension. ASAIO J. 2005;51(4):456-460.
109. Martin J, Siegenthaler MP, Friesewinkel O, et al. Implantable left ventricular assist device for treatment of pulmonary hypertension in candidates for orthotopic heart transplantation-a preliminary study. Eur J Cardiothorac Surg. 2004;25(6):971-977.
110. Salzberg SP, Lachat ML, von Harbou K, et al. Normalization of high pulmonary vascular resistance with LVAD support in heart transplantation candidates. Eur J Cardiothorac Surg. 2005;27(2):222-225.
111. Zimpfer D, Zrunek P, Sandner S, et al. Post-transplant survival after lowering fixed pulmonary hypertension using left ventricular assist devices. Eur J Cardiothorac Surg. 2007;31(4):698-702.
112. Nair PK, Kormos RL, Teuteberg JJ, et al. Pulsatile left ventricular assist device support as a bridge to decision in patients with end-stage heart failure complicated by pulmonary hypertension. J Heart Lung Transplant. 2010;29(2):201-208.
113. Torre-Amione G, Southard RE, Loebe MM, et al. Reversal of secondary pulmonary hypertension by axial and pulsatile mechanical circulatory support. J Heart Lung Transplant. 2010;29(2):195-200.
114. John R, Liao K, Kamdar F, et al. Effects on pre- and posttransplant pulmonary hemodynamics in patients with continuous-flow left ventricular assist devices. J Thorac Cardiovasc Surg. 2010;140(2):447-452.
115. Liden H, Haraldsson A, Ricksten SE, et al. Does pretransplant left ventricular assist device therapy improve results after heart transplantation in patients with elevated pulmonary vascular resistance? Eur J Cardiothorac Surg. 2009;35(6):1029-1034. discussion 1034-5.
116. Mikus E, Stepanenko A, Krabatsch T, et al. Reversibility of fixed pulmonary hypertension in left ventricular assist device support recipients. Eur J Cardiothorac Surg. 2011; Feb 25. [E-pub ahead of print].
117. Athanasuleas CL, Buckberg GD, Stanley AW, et al. Surgical ventricular restoration: the RESTORE Group experience. Heart Fail Rev. 2004;9(4):287-297.
118. Subramanian H, Kunadian B, Dunning J. Is it worth performing surgical ventricular restoration in patients with ischemic cardiomyopathy and akinetic but non-aneurysmal segments in the left ventricle? Interact Cardiovasc Thorac Surg. 2008;7(4):702-707.
119. Jones RH, Velazquez EJ, Michler RE, et al. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med. 2009;360(17):1705-1717.
120. Patel ND, Williams JA, Nwakanma LU, et al. Surgical ventricular restoration for advanced congestive heart failure: should pulmonary hypertension be a contraindication? Ann Thorac Surg. 2006;82(3):879-888. discussion 888.
121. Tatli E, Kurum T, Aktoz M, Buyuklu M. Effects of carvedilol on right ventricular ejection fraction and cytokines levels in patients with systolic heart failure. Int J Cardiol. 2008;125(2):273-276.
122. Quaife RA, Christian PE, Gilbert EM, et al. Effects of carvedilol on right ventricular function in chronic heart failure. Am J Cardiol. 1998;81(2):247-250.
123. Bleeker GB, Schalij MJ, Nihoyannopoulos P, et al. Left ventricular dyssynchrony predicts right ventricular remodeling after cardiac resynchronization therapy. J Am Coll Cardiol. 2005;46(12):2264-2269.